Cell Impact AB (CI) — Cash Flow-to-Debt Ratio
Cell Impact AB (CI) has a Cash Flow-to-Debt Ratio of -0.67x as of September 2025, meaning its operating cash flow of Skr-19.56 Million could theoretically repay -1% of its total liabilities (Skr29.21 Million) in one year. See Cell Impact AB (CI) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cell Impact AB Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Cell Impact AB across 13 annual periods. Also explore CI shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cell Impact AB (2012–2024)
Year-by-year debt coverage analysis for Cell Impact AB. For market capitalisation and broader financial context, see CI market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.48x | Skr-62.23 Million | Skr42.16 Million | ▼ -14.8% |
| 2023 | -1.29x | Skr-100.97 Million | Skr78.56 Million | ▲ +6.4% |
| 2022 | -1.37x | Skr-105.93 Million | Skr77.17 Million | ▼ -53.3% |
| 2021 | -0.90x | Skr-86.08 Million | Skr96.10 Million | ▲ +22.9% |
| 2020 | -1.16x | Skr-47.59 Million | Skr40.99 Million | ▲ +63.2% |
| 2019 | -3.16x | Skr-41.01 Million | Skr12.98 Million | ▼ -40.5% |
| 2018 | -2.25x | Skr-42.57 Million | Skr18.94 Million | ▲ +8.2% |
| 2017 | -2.45x | Skr-15.84 Million | Skr6.47 Million | ▼ -204.4% |
| 2016 | -0.80x | Skr-8.92 Million | Skr11.10 Million | ▲ +22.9% |
| 2015 | -1.04x | Skr-5.56 Million | Skr5.33 Million | ▲ +45.1% |
| 2014 | -1.90x | Skr-5.86 Million | Skr3.08 Million | ▲ +21.2% |
| 2013 | -2.41x | Skr-7.86 Million | Skr3.26 Million | ▼ -13.0% |
| 2012 | -2.13x | Skr-7.80 Million | Skr3.66 Million | — |